Treatment of high-risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes.
Hodgkin lymphoma
LMIC
abandonment
high risk
outcome
treatment
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 Dec 2023
05 Dec 2023
Historique:
revised:
09
11
2023
received:
27
06
2023
accepted:
18
11
2023
medline:
6
12
2023
pubmed:
6
12
2023
entrez:
6
12
2023
Statut:
aheadofprint
Résumé
High-risk Hodgkin lymphoma (HRHL) in children is curable with combined modality therapy. The Association of Pediatric Hematology-Oncology of Central America (AHOPCA) is a consortium of cancer centers from Central America. In 2004, AHOPCA implemented a guideline with a short course of chemotherapy (mStanfordV), strict diagnostics, and radiation guidelines, aimed at reducing abandonment and improving outcomes. Newly diagnosed children less than 18 years of age with high-risk HL (Ann Arbor stages: IIB, IIIB, IV) from AHOPCA centers were staged with chest radiography and ultrasound or computed tomography. Therapy was a modified Stanford V (mStanfordV), substituting cyclophosphamide for mechlorethamine and involved field radiation. Of 219 patients with HRHL, 181 patients were eligible and evaluable; 146 (81%) were boys, 22% being less than 6 years; 43 were stage IIB, 84 IIIB, and 54 IV. Thirty-one (17%) abandoned therapy, 28 (15%) progressed, 30 (17%) relapsed, and eight (4%) died of toxicity. Radiation guidelines were not followed. Five-year abandonment-sensitive event-free survival and overall survival (AS-EFS, AS-OS ± SE) for the cohort were 46% ± 4% and 56% ± 4%; 5-year AS-OS for stages IIB, IIIB, and IV was 76% ± 7%, 59% ± 7%, and 35% ± 7% (p = .0006). Despite instituting a short treatment guideline, it did not improve the abandonment rate (17%) and did not achieve the reported outcomes of Stanford V. The cyclophosphamide dose used to replace merchlorethamine was inadequate. Despite strict guidelines, the radiation therapy application was inaccurate. Weekly chemotherapy may have adversely affected abandonment of therapy by increasing the burden of travel time. Based on these results, AHOPCA established a new abandonment strategy and a new guideline.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
High-risk Hodgkin lymphoma (HRHL) in children is curable with combined modality therapy. The Association of Pediatric Hematology-Oncology of Central America (AHOPCA) is a consortium of cancer centers from Central America. In 2004, AHOPCA implemented a guideline with a short course of chemotherapy (mStanfordV), strict diagnostics, and radiation guidelines, aimed at reducing abandonment and improving outcomes.
METHODS
METHODS
Newly diagnosed children less than 18 years of age with high-risk HL (Ann Arbor stages: IIB, IIIB, IV) from AHOPCA centers were staged with chest radiography and ultrasound or computed tomography. Therapy was a modified Stanford V (mStanfordV), substituting cyclophosphamide for mechlorethamine and involved field radiation.
RESULTS
RESULTS
Of 219 patients with HRHL, 181 patients were eligible and evaluable; 146 (81%) were boys, 22% being less than 6 years; 43 were stage IIB, 84 IIIB, and 54 IV. Thirty-one (17%) abandoned therapy, 28 (15%) progressed, 30 (17%) relapsed, and eight (4%) died of toxicity. Radiation guidelines were not followed. Five-year abandonment-sensitive event-free survival and overall survival (AS-EFS, AS-OS ± SE) for the cohort were 46% ± 4% and 56% ± 4%; 5-year AS-OS for stages IIB, IIIB, and IV was 76% ± 7%, 59% ± 7%, and 35% ± 7% (p = .0006).
CONCLUSION
CONCLUSIONS
Despite instituting a short treatment guideline, it did not improve the abandonment rate (17%) and did not achieve the reported outcomes of Stanford V. The cyclophosphamide dose used to replace merchlorethamine was inadequate. Despite strict guidelines, the radiation therapy application was inaccurate. Weekly chemotherapy may have adversely affected abandonment of therapy by increasing the burden of travel time. Based on these results, AHOPCA established a new abandonment strategy and a new guideline.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30792Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Valsecchi MG, Tognoni G, Bonilla M, et al. Clinical epidemiology of childhood cancer in Central America and Caribbean countries. Ann Oncol. 2004;15(4):680-685. doi:10.1093/annonc/mdh148
Howard SC, Marinoni M, Castillo L, et al. Improving outcomes for children with cancer in low-income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I. Pediatr Blood Cancer. 2007;48(3):364-369. doi:10.1002/pbc.21003
Baez F, Ocampo E, Conter V, et al. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol. 1997;8(3):247-250. doi:10.1023/a:1008200210674
Castellanos EM, Barrantes JC, Baez LF, et al. A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999. Pediatr Blood Cancer. 2014;61(6):997-1002. doi:10.1002/pbc.24905
Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630-637. doi:10.1200/JCO.2002.20.3.630
Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol. 2010;21(3):574-581. doi:10.1093/annonc/mdp337
Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer-the example of mechlorethamine. N Engl J Med. 2012;367(26):2461-2463. doi:10.1056/NEJMp1212468
Jacobs EM, Peters FC, Luce JK, Zippin C, Wood DA. Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA. 1968;203(6):392-398.
Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55(6):1145-1152. doi:10.1002/pbc.22664
Mulvihill DJ, McMichael K, Goyal S, Drachtman R, Weiss A, Khan AJ. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy. Radiother Oncol. 2014;112(2):279-283. doi:10.1016/j.radonc.2014.06.018
Zhou R, Ng A, Constine LS, et al. A comparative evaluation of normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the Childhood Cancer Survivor Study and recent Children's Oncology Group trials. Int J Radiat Oncol Biol Phys. 2016;95(2):707-711. doi:10.1016/j.ijrobp.2016.01.053
Quintana Y, Patel AN, Arreola M, Antillon FG, Ribeiro RC, Howard SC. POND4Kids: a global web-based database for pediatric hematology and oncology outcome evaluation and collaboration. Stud Health Technol Inform. 2013;183:251-256.
Mostert S, Arora RS, Arreola M, et al. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group. Lancet Oncol. 2011;12(8):719-720. doi:10.1016/S1470-2045(11)70128-0
Friedrich P, Ortiz R, Strait K, et al. Pediatric sarcoma in Central America: outcomes, challenges, and plans for improvement. Cancer. 2013;119(4):871-879. doi:10.1002/cncr.27816
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481. doi:10.1080/01621459.1958.10501452. 1958/06/01
Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35(1):1-39. doi:10.1038/bjc.1977.1
Castellino SM, Pei Q, Parsons SK, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma. N Engl J Med. 2022;387(18):1649-1660. doi:10.1056/NEJMoa2206660
Mauz-Korholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022;23(1):125-137. doi:10.1016/S1470-2045(21)00470-8
Friedrich P, Lam CG, Kaur G, Itriago E, Ribeiro RC, Arora RS. Determinants of treatment abandonment in childhood cancer: results from a global survey. PLoS One. 2016;11(10):e0163090. doi:10.1371/journal.pone.0163090
Friedrich P, Lam CG, Itriago E, Perez R, Ribeiro RC, Arora RS. Magnitude of treatment abandonment in childhood cancer. PLoS One. 2015;10(9):e0135230. doi:10.1371/journal.pone.0135230
Cohen P, Friedrich P, Lam C, et al. Global access to essential medicines for childhood cancer: a cross-sectional survey. J Glob Oncol. 2018;4:1-11. doi:10.1200/JGO.18.00150
Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28(23):3680-3686. doi:10.1200/JCO.2009.26.9381
Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019;187(1):39-48. doi:10.1111/bjh.16014
Seror E, Donadieu J, Pacquement H, et al. Combined therapy in children and adolescents with classical Hodgkin's lymphoma: a report from the SFCE on MDH-03 national guidelines. Pediatr Hematol Oncol. 2016;33(7-8):423-437. doi:10.1080/08880018.2016.1247393
Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22(1):62-68. doi:10.1200/JCO.2004.01.021
Alvarez E, Seppa M, Rivas S, et al. Improvement in treatment abandonment in pediatric patients with cancer in Guatemala. Pediatr Blood Cancer. 2017;64(10):e26560. doi:10.1002/pbc.26560
Graetz D, Rivas S, Fuentes L, et al. The evolution of parents' beliefs about childhood cancer during diagnostic communication: a qualitative study in Guatemala. BMJ Glob Health. 2021;6(5):e004653. doi:10.1136/bmjgh-2020-004653
Castellanos EM. A risk-adapted, response-based therapeutic regimen using OEPA/COPDAC for the treatment of children with high-risk Hodgkin lymphoma: from the AHOPCA group. Paper presented at: CAYAHL, a session of global collaborations in pediatric Hodgkin lymphoma; 2017.
WHO. CureAll Framework: WHO global initiative for childhood cancer. Increasing access, advancing quality, saving lives. IRIS WHO publication repository. World Health Organization; 2021.